Most published studies of tight glucose control in hyperglycaemic critically ill patients did not evaluate this potentially important issue [5] [6] [7] [8] . The first work that shed light on glycaemic variability in critically ill patients was a multi-centre retrospective observational study 9 which showed that both the mean and standard deviation (SD) of blood glucose (BG) were significantly associated with increased intensive care unit (ICU) mortality (odds ratios [OR] per 1 mmol 1.23 and 1.27, respectively) 9 . The findings suggested that glycaemic variability might have a bigger effect on ICU outcomes than hyperglycaemia itself. Additionally, Krinsley found that the SD of mean BG during ICU stay was also an independent risk factor for mortality in a mixed medical surgical ICU, especially in patients with euglycaemia 10 . Thus, the objective of this study was to assess the association between glycaemic fluctuation (GF), another marker of glycaemic variability, and various outcomes of critically ill patients treated with insulin for hyperglycaemia. 
MATERIAlS AND METHODS

Study population
This study was a nested cohort of a randomised controlled trial that compared intensive insulin therapy (IIT, target BG of 4.4 to 6.1 mmol/l) with conventional insulin therapy (CIT, target BG of 10.0 to 11.1 mmol/l). The original trial was conducted in a 21-bed closed medical surgical ICU of King Abdulaziz Medical City, in a tertiary-care teaching hospital in Riyadh, Saudi Arabia. Details of the clinical trial have been published elsewhere 11 . In brief, the patients were critically ill adults with BG >6.1 mmol/l during the first 24 hours of ICU admission. After randomisation, nurses measured BG hourly using arterial or capillary whole blood samples using a glucose analyser (Accu-Check Inform meter, Roche, Mannheim, Germany). This frequency was reduced to every two to four hours when measurements were stable and was increased when the BG concentration dropped to ≤3.2 mmol/l. Both groups received regular insulin (Humulin R, Eli lilly and Company, Indianapolis, IN, USA) as intravenous infusion according to a protocol. The trial showed no significant difference in ICU mortality between the IIT and CIT groups (Adjusted Hazard Ratio 1.09, 95% confidence interval [CI] 0.70 to 1.72) 11 . All of the 523 patients in the original trial were included in the current study.
Data collection
The following daily glycaemic indices were extracted: the highest, lowest and mean BG concentrations. We then calculated the daily range of BG for each patient and defined GF as the mean range during ICU stay. The median of GF was found to be 6.0 mmol/l, hence we divided patients into two groups: narrow GF if <6.0 mmol/l and wide GF if ≥6.0 mmol/l. GF was also divided into quartiles, where each quartile represented the 25% of all patients whose GF fell within the following ranges: quartile 1: <4.0 mmol/l; quartile 2: 4.0 to 5.9 mmol/l; quartile 3: 6.0 to 7.9 mmol/l; quartile 4: ≥8.0 mmol/l. Additional collected data included age, gender, body mass index, history of diabetes mellitus, reason for ICU admission (postoperative or medical), presence of sepsis on ICU admission, admission Acute Physiology and Chronic Health Evaluation II score, admission creatinine and international normalised ratio, requirement for mechanical ventilation and its duration, use of vasopressors (defined as the use of any vasopressor infusion except dopamine <5 µg/kg/minute) in the first 24 hours of ICU admission, daily caloric intake and the average daily dose of insulin. Since there is no gold standard surrogate for glycaemic variability and GF was not used previously as an indicator of glycaemic variability in critically ill patients, we correlated GF with the SD of BG by performing linear correlation between the glycaemic range and the respective BG SD in 102 randomly selected patient days and found a correlation coefficient of 0.93 (P <0.001).
Outcome measures
The primary outcome measure was ICU mortality. The secondary outcomes were rates of ICU-acquired infections (defined according to the National Nosocomial Infections Surveillance System 12 ), mechanical ventilation duration, ICU and hospital stay and mortality.
Statistical analysis
Continuous variables were presented as means and SD, whereas categorical variables were summarised by numbers and percentages. Differences between wide and narrow GF groups were assessed using the Student's t-test or chi-square test as appropriate.
Stepwise, multiple logistic regression models were used to study the predictors of GF and to evaluate glucose range as an independent predictor of outcome. The variables entered into the model included age, gender, diabetes history, body mass index, admission diagnosis, sepsis on admission to ICU, admission creatinine, admission international normalised ratio, Acute Physiology and Chronic Health Evaluation II score, mechanical ventilation requirement, ICU stay, use of vasopressors, average insulin used per day and randomisation to either IIT or CIT. A P value less than 0.05 was considered statistically significant. All statistical analyses were performed using SAS software (version 8.0; SAS Institute, Cary, North Carolina, USA).
RESUlTS
Patients characteristics and glycaemic fluctuation
The major demographic and clinical characteristics of the study population are described in Table 1 . Of note, 75% of patients were male, 40% had diabetes history and 85% received mechanical ventilation. Table 1 also describes patient characteristics according to GF. Patients with wide GF had higher admission BG and higher mean BG during ICU stay. Of interest, wide GF was associated with older age, female gender, diabetes history, non-surgical ICU admission, higher severity of illness, sepsis on admission and higher creatinine. Patients with wide GF required higher insulin doses. There was no significant relationship between use of catecholamines and GF.
When evaluating the predictors of GF, we found that age (OR 1.03 for every additional year, 95% CI 1.02 to 1.05), diabetes history (OR 3.00, 95% CI 1.74 to 5.17), CIT (OR 4.54, 95% CI 2.44 to 8.33) and daily dose of insulin (OR 1.04, 95% CI 1.03 to 1.05) were independent predictors of wide GF. Interestingly, increased body mass index was associated with decreased odds of GF (OR 0.92, 95% CI 0.89 to 0.96) and daily caloric intake had neutral effect (OR 1.00, 95% CI 0.99 to 1.00).
Relationship between glycaemic fluctuation and outcomes
The ICU and hospital mortality for the study cohort were 15.3 and 29.6%, respectively. Table 2 depicts the relationship between GF and patient outcomes. Crude ICU mortality was significantly higher in patients with wide GF (22.2 vs 8.4%, P <0.001). Figure 1 describes the relationship between GF quartiles and ICU mortality. It shows that ICU mortality was directly proportional to the degree of GF. Actually, ICU mortality quadrupled from the first to the fourth GF quartile. Similar association was seen between hospital mortality and GF quartiles. Nevertheless, we did not find any association between GF and the duration of mechanical ventilation, ICU or hospital stay ( Table 2) . When evaluating the predictors of patients' outcomes, we found that GF, but not mean BG during ICU stay, was associated with increased ICU mortality (OR per mmol, 1.08, 95% CI 1.00 to 1.18) and hospital mortality (OR per mmol 1.09, 95% CI 1.02 to 1.17) ( Table 3) . Neither GF nor mean BG was associated with the development of ICUacquired infections. 
Type of insulin therapy and glycaemic fluctuation
There was no significant difference in GF between IIT and CIT groups (GF 6.2±2.6 and 6.4±4.0 mmol/l respectively, P=0.46). We also evaluated the temporal changes in glycaemic range and daily insulin requirements for up to seven days of ICU stay in both narrow and wide GF groups (Figure 2 ). We found that while insulin requirement remained stable, glycaemic range progressively decreased over time in both groups. Figure 3 describes the mortality of patients in the two treatment groups according to GF. Wide GF was associated with higher ICU and hospital mortality in both treatment groups (P <0.01).
DISCUSSION
The main finding of this study was that GF during the course of critical illness was an independent predictor of ICU and hospital mortality. This suggests that minimising glycaemic excursions might be an important therapeutic goal in critically ill patients.
Most studies that evaluated hyperglycaemia in critically ill patients and the effects of tight glucose control by insulin focused on inclusion BG and the mean during ICU stay as the main glycaemic indices in relation to patient outcomes 3,5-7 . However, there is a growing interest in looking at glycaemic variability in critically ill patients 13 . This interest originated from evidence that glucose variability is harmful in diabetic patients. The analysis of the well known 'Diabetes complications and control trial' showed that even when haemoglobin A1Cs were comparable, conventionally treated type-I diabetic patients experienced increased progression to retinopathy over time compared to intensely treated patients 1 . This is thought to be due to the higher frequency and magnitude of glycaemic excursions in conventionally treated patients because they received insulin less frequently 1 . Muggeo et al followed 1409 type-II diabetic patients aged 56 to 74 years for 10 years and fiGure 2: Temporal changes in mean glycaemic range and insulin dose in narrow and wide glycaemic fluctuation groups (< and ≥6 mmol/l respectively). While insulin requirement remained stable, there was a progressive decrease in glycaemic range in the first seven days of intensive care unit stay in both groups. ICU=intensive care unit. found that the coefficient of variation of fasting BG was an independent predictor of total, cardiovascular and cancer mortality 2 . Two retrospective studies evaluated glucose variability in critically ill adult patients and showed that the BG SD was a significant independent predictor of ICU mortality 9, 10 . In a retrospective evaluation of 1267 patients with sepsis, 63% of whom required ICU admission, Ali et al evaluated three different indicators of glycaemic variability, BG SD, mean amplitude of glycaemic excursions and glycaemic liability index and found that all of these indicators had modest discrimination ability for hospital mortality (area under the receiver operating characteristic curve 0.62, 0.59 and 0.67, respectively) 14 . Another retrospective study in a paediatric ICU used another index of glycaemic variability, the glucose variability index, and found that glucose variability had an independent relationship with death (P=0.0002) 15 . Our study evaluated a different indicator of glycaemic variability, the fluctuation of BG between the highest and lowest concentrations. This indicator has been described among many others as a marker of glycaemic variability 16 . Our finding of a significant association between GF and mortality in critically ill patients may reflect a harmful effect of blood glucose excursions. However, the use of multivariate analysis cannot entirely exclude the effect of unmeasured confounders and as such the association of GF and increased mortality may also reflect a surrogate marker of severity of illness or other confounding factors such as patient genotype.
The pathophysiologic basis for the potential adverse effects of glycaemic variability is not fully understood. Multiple in vitro and vivo studies have shown that BG excursions have more adverse effects than those of chronic stable hyperglycaemia [17] [18] including increased production of reactive oxygen species, such as peroxynitrite and superoxide 17 , leading to cellular damage. Through these effects, GF may contribute to organ dysfunction and thus increased mortality.
The factors that lead to glycaemic variability in critical illness are not well known. Although Acute Physiology and Chronic Health Evaluation II scores were significantly higher in the wide GF group, it was not an independent predictor of GF when multivariate logistic regression analysis was done. Abrupt changes in dextrose infusions, feeding interruption and medications commonly used in ICUs, such as corticosteroids, may be contributing factors. Interestingly, we found no significant association between vasopressor use or daily caloric intake and GF. The insulin protocol itself may provoke such excursions, especially if there were quick and steep changes in insulin infusion rates.
Of note, we found that both IIT and CIT had a similar degree of GF. Although IIT was expected to narrow glycaemic excursions, it may have contributed to rapid glycaemic swings. IIT protocol dictated that BG be actively lowered to the euglycaemic range by increasing the insulin dose when patients had hyperglycaemia and that patients be given 50% dextrose intravenously when experienced hypoglycaemia or 10% destrose intravenous infusion when kept fasting. Moreover, the higher frequency of BG measurements demanded by the IIT protocol may have uncovered wider GF by itself. Nevertheless, as the two groups had similar outcomes, one potential explanation is that the benefit of insulin therapy was neutralised by GF. The observation that GF decreased progressively over time in the two groups could be related to the earlier death of the more severely ill patients with higher GF or to the progressive recovery of insulin resistance as patients become more stable. Different IIT protocols may be associated with different GF, which may be responsible for different outcomes in different studies. The studies that have shown benefit from IIT demonstrated that such therapy reduced glycaemic variability. In the first trial by Van den Berghe et al, BG SD in the CIT group was bigger than in the IIT group (1.8 and 1.0 mmol/dl, respectively) 19 . Similarly, in a report that showed the ability of intensive control to reduce nosocomial infection rate in the surgical ICU, BG SD was 3.4 mmol/l for CIT and 2.0 mmol/l for IIT 20 . In contrast, the difference in BG SD was smaller in the NICE-SUGAR study (1.3 mmol/l for CIT and 1.0 mmol/l for IIT) and that was associated with no benefit from IIT 8 . These studies did not intend to study the relationship between glycaemic variability and outcome of patients, but the above observations suggest that glycaemic variability might have an effect on the outcomes of critically ill patients. To clarify this further, it might be essential to compare the effects of two treatment protocols with similar BG target, one of which achieves significantly lower glucose variability than the other. A potential management strategy to reduce glycaemic variability is the use of continuous glucose monitoring connected to an insulin infusion pump through a programmed computer. This system would automatically adjust insulin infusion rates according to measured BG. Real-time continuous glucose monitors are starting to appear in the marketplace 21 and have been proven to significantly improve glycaemic excursions in diabetic patients by reducing exposure to hyperglycaemia without increasing the risk of hypoglycaemia 22 .
The strengths of this study include the prospective data collection, the protocolised treatment with insulin and the use of an easily observed indicator of glycaemic variability, which is the glycaemic range. Unlike mean amplitude of glycaemic excursions, glycaemic lability index and even the BG SD, all of which require complex mathematical calculations, glycaemic range is easily observed during daily ICU rounds. Adding strength to this indicator is our finding of strong correlation between daily glucose range and respective BG SD. On the other hand, there are several limitations. The study was done at a single institution and only one indicator of glycaemic variability was studied. This indicator may not accurately reflect the degree and frequency of BG excursions. However, there is no one universal definition of glycaemic variability. The use of pointof-care glucometers, including Accuchek, has its limitations with reported overestimation of BG in 14% of patients in one study 23 . Another study showed a mean difference of 0.6 mmol/l between whole and central laboratory BG 24 . Therefore, it is possible that inaccurate measurement in patients being treated with intensive insulin therapy leads to necessary changes in the insulin infusion rates and may itself contribute to the measured glucose variability. Nevertheless, these limitations exist with most point-of-care glucometers 23 which are still commonly used to monitor BG and guide insulin therapy in critically ill patients and have been used in various trials that compared IIT and CIT 4, 6, 8, 11 . Additionally, it is unlikely that the observed association of GF and mortality is related entirely to the use of point-of-care devices and is likely to be seen even when more accurate measures of blood glucose are used.
In conclusion, we have demonstrated that glycaemic fluctuation is common in critically ill patients and is associated with higher ICU and hospital mortality. Additional studies to confirm the clinical significance of glycaemic variability and then to evaluate the effect of reducing such variability in critically ill patients are needed. Management of critically ill patients may now have a new goal, which is to control glycaemic variability.
